HCV Genotypes 5 and 6
"HCV Next" offers information on a range of topics, which include diagnosis, new combination therapies, side effects, drug/drug interaction, guidelines, practice management issues, to name a few.
The following articles appeared in the January print edition of HCV NEXT, provided online at Healio.
2015: The Good The Bad The Ugly
"HCV Next" offers information on a range of topics, which include diagnosis, new combination therapies, side effects, drug/drug interaction, guidelines, practice management issues, to name a few.
The following articles appeared in the January print edition of HCV NEXT, provided online at Healio.
EDITORIAL
Looking Back, Looking Ahead at Treatment Developments2015: The Good The Bad The Ugly
HCV Next, January 2016
After 2014, a year of first implementations of direct-acting antiviral therapies, 2015 brought even more changes and challenges in hepatitis C virus research, diagnosis, treatment and access.
We saw much good: approvals in difficult-to-treat genotypes, breakthrough designations for soon-to-come drugs that hold promise for underserved populations and a successful continuous updating of the HCV guidelines document jointly maintained by the AASLD and IDSA.
Yet there was the bad: real-world experiences with rapidly approved drugs proven to produce drug-drug interactions and unforeseen toxicities.
And the ugly seems to be getting uglier, with ongoing denials of treatment for patients who have not yet progressed in severity of their disease.
Please see my Looking Back, Looking Ahead article for a more detailed breakdown on what 2015 brought to our community and what I foresee in the coming year.
— Michael S. Saag, MD
Co-Chief Medical Editor
HCV Next
Table of Contents
IN THE JOURNALS
HCV increases chronic kidney disease risk
Hepatitis C increases risk of cardiovascular mortality
Simulation: Universal prison-based screening reduces HCV transmission
MEETING NEWS COVERAGE
After 2014, a year of first implementations of direct-acting antiviral therapies, 2015 brought even more changes and challenges in hepatitis C virus research, diagnosis, treatment and access.
We saw much good: approvals in difficult-to-treat genotypes, breakthrough designations for soon-to-come drugs that hold promise for underserved populations and a successful continuous updating of the HCV guidelines document jointly maintained by the AASLD and IDSA.
Yet there was the bad: real-world experiences with rapidly approved drugs proven to produce drug-drug interactions and unforeseen toxicities.
And the ugly seems to be getting uglier, with ongoing denials of treatment for patients who have not yet progressed in severity of their disease.
Please see my Looking Back, Looking Ahead article for a more detailed breakdown on what 2015 brought to our community and what I foresee in the coming year.
— Michael S. Saag, MD
Co-Chief Medical Editor
HCV Next
IN THE JOURNALS
HCV increases chronic kidney disease risk
Hepatitis C increases risk of cardiovascular mortality
Simulation: Universal prison-based screening reduces HCV transmission
MEETING NEWS COVERAGE
SPECIAL SERIES
THE BIG PICTURE
TREND WATCH
Roche Releases New Assays for HIV-1, HCV and HCV Genotyping
Medicines Patent Pool Expands to Include Medicines for HCV, TB
FDA Accepts NDA for Review of 3D Regimen
Gilead Submits MAA for Sovaldi/velpatasvir to EMA
Medicines Patent Pool Expands to Include Medicines for HCV, TB
FDA Accepts NDA for Review of 3D Regimen
Gilead Submits MAA for Sovaldi/velpatasvir to EMA
No comments:
Post a Comment